FGD5 and carcinoma: FGD5-AS1, a recently characterized lncRNA, has been observed in diverse carcinomas, including lung cancer (13, 15, 16), ovarian cancer (17) gastric cancer (GC) (18, 19), melanoma (20), hepatocellular carcinoma (21), glioblastoma carcinoma (22, 23), osteosarcoma carcinoma (24), and breast cancers (25), From a clinical perspective, there was a strong correlation observed between elevated levels of FGD5-AS1 and poor OS as well as clinicopathological features for example progressed tumor stage, presence of LNM, and larger tumor size (17, 24).